Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
PHOENIX, July 20, 2017 -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its second quarter 2017 financial results on Thursday, August 3, 2017, before the U.S. financial markets open.
Following the release of the financial results, Saeed Motahari, President and Chief Executive Officer, and Darryl S. Baker, Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Daylight Time.
Interested parties may participate in the conference call by dialing (844) 263-8304 (U.S.) or (213) 358-0958 (International), 5-10 minutes prior to the start of the call. A replay will be available shortly after the completion of the call for one week by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International) and entering conference call ID number 55335437.
A live audio webcast and archive of the call will also be available at www.insysrx.com.
About Insys
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets one product, SUBSYS® (fentanyl sublingual spray) and has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact: Lisa M. Wilson T: 212-452-2793 E: [email protected]
